New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization ...
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, ...
Post-radiation cisplatin and etoposide as systemic treatment in newly diagnosed adult medulloblastomas: A retrospective, single institution, longitudinal evaluation of clinical outcomes and toxicity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results